Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP88102.RAMAzi59BpupfBVzpQ6Nalvd_TyWnMLEYrYgWkDF6yqHQ130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP88102.RAMAzi59BpupfBVzpQ6Nalvd_TyWnMLEYrYgWkDF6yqHQ130_assertion type Assertion NP88102.RAMAzi59BpupfBVzpQ6Nalvd_TyWnMLEYrYgWkDF6yqHQ130_head.
- NP88102.RAMAzi59BpupfBVzpQ6Nalvd_TyWnMLEYrYgWkDF6yqHQ130_assertion description "[In this first study applying new TFC to patients suspected of ARVD/C, 64% of probable ARVD/C patients and 11% of family members were additionally diagnosed. ECG criteria and pathogenic mutations especially contributed to new diagnosis. Newly proposed TFC have a major impact in increasing diagnostic yield of ARVD/C.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP88102.RAMAzi59BpupfBVzpQ6Nalvd_TyWnMLEYrYgWkDF6yqHQ130_provenance.
- NP88102.RAMAzi59BpupfBVzpQ6Nalvd_TyWnMLEYrYgWkDF6yqHQ130_assertion evidence source_evidence_literature NP88102.RAMAzi59BpupfBVzpQ6Nalvd_TyWnMLEYrYgWkDF6yqHQ130_provenance.
- NP88102.RAMAzi59BpupfBVzpQ6Nalvd_TyWnMLEYrYgWkDF6yqHQ130_assertion SIO_000772 20215590 NP88102.RAMAzi59BpupfBVzpQ6Nalvd_TyWnMLEYrYgWkDF6yqHQ130_provenance.
- NP88102.RAMAzi59BpupfBVzpQ6Nalvd_TyWnMLEYrYgWkDF6yqHQ130_assertion wasDerivedFrom gad-20130706 NP88102.RAMAzi59BpupfBVzpQ6Nalvd_TyWnMLEYrYgWkDF6yqHQ130_provenance.
- NP88102.RAMAzi59BpupfBVzpQ6Nalvd_TyWnMLEYrYgWkDF6yqHQ130_assertion wasGeneratedBy ECO_0000203 NP88102.RAMAzi59BpupfBVzpQ6Nalvd_TyWnMLEYrYgWkDF6yqHQ130_provenance.